首页 › 期刊 › Translational Breast Cancer Research
Translational Breast Cancer Research
出版商:AME Publishing Company · ISSN:2218-6778 · 国家/地区:HK · 类型:journal · 官网:http://tbcr.amegroups.com/
研究主题:Breast Cancer Treatment Studies · Advanced Breast Cancer Therapies · HER2/EGFR in Cancer Research · Cancer Treatment and Pharmacology · Breast Lesions and Carcinomas
数据覆盖:7 个公开学术数据源交叉核验(crossref、jcr、openalex、scimago、wikidata、xr、cwts)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):3.900
- JCR 分区:Q2(ONCOLOGY)
- 新锐分区(2026):医学 4区
- SJR:0.891(Q1),2025 年,Hong Kong
- CWTS 2025:SNIP 0.861 · IPP 2.852 · 自引率 2.2%
- h-index:13
- i10 指数:28
- 近两年篇均被引:3.60
- 载文量 255 · 总被引 1122
- Crossref DOI 总量:254,近期 118
逐年趋势
- 近年影响因子:2024 1.4
- 近年 SJR:2024 0.283(Q3) → 2025 0.891(Q1)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Cancer — IF 60.7 · JCR Q1 · 中科院1区(Top)
- Journal of Clinical Oncology — IF 44.7 · JCR Q1 · 中科院1区(Top)
- The Lancet Oncology — IF 33.7 · JCR Q1 · 中科院1区(Top)
- Cancer Discovery — IF 29.5 · JCR Q1 · 中科院1区(Top)
- Cancer Communications — IF 28.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Translational Breast Cancer Research》的影响因子是多少?
根据 JCR 2025 年数据,《Translational Breast Cancer Research》的最新影响因子(IF)为 3.900。
《Translational Breast Cancer Research》是几区期刊?
《Translational Breast Cancer Research》JCR 分区为 Q2。
本刊近期代表论文
- Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association (2026)
- Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer (2025 · 被引 1)
- Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer (2024 · 被引 7)
- Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era (2023 · 被引 10)
- Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022 (2022 · 被引 73)
- Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study (2020 · 被引 111)